Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Carcinoma, Renal Cell
Interventions: GW786034 (pazopanib), Probe drugs; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pharmacokinetics, Healthy
Interventions: Colchicine, Cyclosporine; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Pirfenidone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
Interventions: SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 19 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Healthy
Interventions: ABBV-CLS-7262; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Chemotherapy-Related Cognitive Impairment, Healthy
Interventions: Usability study; Other
Lead sponsor: Bright Cloud International Corp; Industry
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: North Brunswick, New Jersey

Conditions: Acetaminophen Metabolism, Acetaminophen Poisoning, Drug Metabolism by Excipients
Interventions: Acetaminophen liquid formulation, Acetaminophen solid formulation; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease, Constipation
Interventions: OMM treatment; Procedure
Lead sponsor: New York Institute of Technology; Other
Eligibility: 40 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: COVID-19
Interventions: GAMUNEX-C, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more

Conditions: Sleep Apnea
Interventions: Dextromethorphan, Caffeine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 4 Years to 16 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Louisville, Kentucky • Richmond, Virginia

Conditions: Drug Addiction, Smoking Cessation
Interventions: Nicotine transdermal system, Nicotine containing cigarette, Placebo cigarette; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C Virus
Interventions: Ortho Tri-Cyclen®, BMS-650032; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Dyslipidemias
Interventions: 40 mg Pravastatin (Pravachol), 20 mg Simvastatin, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 20 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions: Pantoprazole, High-dose methotrexate infusion duration; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Ginseng, Ginkgo; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 20 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Liver Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer
Interventions: Standard microcatheter, PEDD device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
Interventions: Efavirenz, Quizartinib; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions: TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
Interventions: Ibuprofen and PRP, Acetaminophen and PRP, Placebo and PRP; Combination Product
Lead sponsor: QC Kinetix LLC; Industry
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Alzheimer's Disease
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Ovarian Cancer
Interventions: Acupuncture; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Forearm blood flow, Microneurography, Rhythmic handgrip exercise, Lower body negative pressure, Angiotensin II; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study

Effect on Acetaminophen Metabolism by Liquid Formulations

Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

Drug Interaction Oral Contraceptive Pill (OCP)

Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Effects of Ginseng and Ginkgo on Drug Disposition in Man

Pressure-enabled Delivery in Radioembolization (TriNav Study)

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Acupuncture to Improve Quality of Life in Patients With Advanced Cancer

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients